Background. p16
INTRODUCTION
Normal human cells undergo a finite number of cell divisions and ultimately enter a nondividing state called replicative senescence [1] . Replicative or cellular senescence was observed and proposed as an experimental model for aging at the cellular level over thirty years ago. Senescent cells remain metabolically active and show characteristic changes in cell morphology, physiology and gene expression [2] [3] [4] . The mechanism of aging is very complex and it implicates genetics, environment, psychology and sociology, while the genetic factor is critical for life span. There are several independent pathways that control the process of replicative senescence in human cells [5] [6] [7] [8] [9] . Such pathways often involve the activation of the cell cycle inhibitors, p21 CIP1/WAF1 [10] [11] [12] and p16
INK4a [13] [14] [15] [16] [17] [18] , which are likely the genes that act to induce cellular senescence, and are in fact direct targets of the genetic program that leads cells to senescence [19, 20] .
It is well known that p16 INK4a inhibits cdk (cyclin-dependent kinase)4/cdk6-mediated phosphorylation of retinoblastoma gene product (pRb) and induces cell cycle arrest in G1 phase [21] , p16
INK4a up-regulation is also a key event in the terminal stages of growth arrest in senescence. The mechanism of increased p16
INK4a expression in senescent cells is not well understood. We and others previously reported that some regulatory factors, such as Bmi-1, Ets, Id1, E47, Jun B, p21 CIP1/WAF1 and ITSE binding factor, were involved in p16
INK4a transcription [22] [23] [24] [25] [26] [27] . Here we show that transcription factor Sp1 also plays an important role in the regulation of p16
INK4a gene expression during senescence. The increase of Sp1 binding activity rather than the protein level in senescent fibroblasts contributes to the high levels of p16 INK4a expression during the progress of aging. What's more, the basal level of Sp1 is essential for this effect.
MATERIALS AND METHODS

Cell culture
Human embryonic lung fibroblast cell line (2BS cells) obtained from the National Institute of Biological Products (Beijing, China), was cultured in DMEM medium, containing 10% fetal bovine serum, 100 U/ml penicillin and 1 mg/ml streptomycin [28, 29] .
Plasmids construction
To make pGL3-620, 620bp 59-fragment of human p16INK4a promoter was digested with Rsa I and Hind III from pSIR-870-EGFP, and inserted into pGL3-Basic Luciferase Report Vector (Promega). Site-directed mutagenesis was conducted using Quickchange TM Site-directed mutagenesis Kit (Stratagene) according to the manufacturer's protocol. Five oligo nucleotides carrying mismatched bases: 59-GGAAGGAAACGGatCcGGGGCGGAT-TTC-39, 59-GGCGGGGGCaGATcTCTTTTTAACAGAG-39, 59-GGGAGGCCGGAtccCGGTGTGGGGGG-39, 59-CAGAGGGTGGGGgGatCCGAGTGCGCTC-39 and 59-GCAGGCAGCGGGatcCGGGGAGCAGC-39 were used to mutagenize the segments containing GC boxes spanning from nt (nucleotide) 2474 to 2447, 2462 to 2435, 2380 to 2355, 276 to 249 and 226 to 21 upstream of translational start site respectively (Table 1 ). The nucleotide sequences of the mutants were confirmed by sequencing. Expression plasmids of Sp1 and Sp3 were kindly provided by Dr. Robert Tjian (University of California, Berkeley, CA) and Dr. G. Suske (IMT, Marburg, Germany) respectively. The pCMV plasmid without an insert served as the control.
Transfection and luciferase activity assays
All plasmids were purified with Qiagen Plasmid Midi Kits (Chatsworth, CA). For each transfection experiment, 2BS cells were seeded at 12-well plates and grown for about 24 h until they were above 90% confluent, then transfected with an equal amount of reporter plasmid (1.6 mg) and 0.32 mg of pRL-CMV (Promega) as transfection efficiency control, using lipofectamine 2000 (Invitrogen) and following the manufacturer's indications. Five hours later, serum-free DNA-containing medium was replaced by fresh growth medium and the cells were harvested 48h after transfection. Luciferase assays were performed as described (DualLuciferase Reporter Assay System, Promega). All assays were carried out in triplicate and performed twice for confirmation.
RNA analysis
Total RNA was prepared from exponentially growing cells using RNeasy Mini Kit (Qiagen, Hilden, Germany). For Northern blot analysis, RNA was electrophoresed in 1.5% formaldehydedenaturing agarose gel, with the 0.24-9.5 kb RNA Ladder included in one lane as a size marker (Gibco BRL, Gaithersburg, MD). RNA was then transferred onto Biodyne B membrane (Pall, East Hills, NY) according to manufacturer's recommendations and fixed. The human p16
INK4a gene-coding region was used as probe labeled with [a-32 P] dCTP (Yahui, Beijing, China) by random priming using the Prime-a-Gene Labeling System (Promega). Hybridization was carried out in ExpressHyb TM Hybridization Solution (Clontech) at 68uC for 1 h. The blot was stringently washed with 0.16SSC, 0.1% SDS at 68uC for 15 min twice. Autoradiography was performed at 280uC. The same blot was stripped after probing and then reprobed with the 32 P-labeled GAPDH probe to control for equivalent RNA loading in each lane.
Western blot
Cell extracts were prepared following standard procedures. Briefly, three to five volumes of lysis buffer (50 mM Tris-HCL, pH 7.4, 0.25 M NaCl, 0.1% Triton-X-100, 1 mM EDTA, 50 mM NaF, 1 mM DTT, 0.1 mM Na 3 VO 4 ) were added to a cell pellet. The following protease inhibitors were added: 0.1 mM PMSF, 1 mg/ ml leupeptin, 1 mg/ml aprotinin). After incubation on ice for 30 min, samples were centrifuged at 14,000 r.p.m. for 5 min at 4uC to recover the supernatant. After proteins were electrophoresed in a 15% (for p16) or 8% (for Sp1/Sp3) denaturing polyacylamide gel and transferred to a PVDF membrane, the membrane was blocked in 5% nonfat milk-TBS-0.25% Tween 20 for 1 h and incubated with the primary antibody in TBS-0.25% Tween 20 for 1 h at room temperature. Complexes were detected with horseradish peroxidase-linked secondary antibody and enhanced chemiluminescence (SuperSignal, Pierce). The primary and secondary antibodies used in this study were all from Santa Cruz Biotechnology (Santa Cruz).
Preparation of nuclear extracts
Nuclear extracts from 2BS cells were prepared as follows: About 1610 6 cells were harvested, washed twice with cold PBS (phosphatebuffered saline) and collected by centrifugation at 3500 rpm at 4uC for 5 min. The cells were resuspended in 400 ml of solution I (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM DTT, 0.5 mM PMSF) and lysed by passing them through a 25 gauge syringe. Nuclei were pelleted at 2,000 r.p.m for 10 min, washed once with solution I and resuspended in 200 ml of solution II (solution I with 5% glycerol, 400 mM NaCl and without KCl). The suspension was rotated at 4uC for 30 min and then centrifuged at 14,000 r.p.m, 4uC, for 30 min. The resulting clear supernatant was stored at 280uC until use.
Electrophoretic mobility shift Assay (EMSA) and supershift assay
A 38 bp long oligonucleotide 59-GGAAGGAAACGGGGCGG-GGGCGGATTTCTTTTTAACAG-39 (oligo I) extending from nt 2474 to 2437 or a 28 bp long oligonucleotide 59-CAGAGGG-TGGGGCGGACCGAGT GCGCTC-39 (oligo II) extending from nt 276 to 249 on the 59 UTR of p16 gene, was used in EMSA and supershift assay. Double stranded DNA fragments were end-labeled with [c- 32 P] dATP (Yahui, Beijing, China) and T4 polynucleotide kinase (New England Biolabs, Beverly, MA). The probes were purified using QIAquick Nucleotide Removal Kit (Qiagen) and 15,000 cpm were incubated for 25 min on ice with 10 mg of nuclear extract from 2BS cell line, in the presence of 20 mM Tris-HCl pH 7.5, 75 mM KCl, 3.5 mM DTT, 20 nM ZnCl 2 , 1 mg/ml BSA, 5% glycerol and 1 mg poly (dI-dC) (Pharmacia Biotech, Piscataway, NJ) in a total volume of 20 ml. For supershift experiments, 2 mg of antibody against Sp1 or Sp3 (Santa Cruz Biotechnology, Santa Cruz, CA) was incubated for 20 min on ice with the nuclear extract before adding the labeled probe. DNA/protein complexes were separated from free DNA on a 5% polyacrylamide gel in TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA) at 4uC for 120 min at 340 V. After electrophoresis, gels were dried and autoradiographed.
Chromatin immunoprecipitation (ChIP)
ChIPs were performed using the Chromatin Immunoprecipitation Assay Kit (Upstate, New York) according to manufacturer's instruction. In brief, 1610 6 cells were crosslinked by adding formaldehyde directly to cell culture media and incubated for 10 min at 37uC. Wash cells twice with cold PBS and then cells were scraped and resuspended in 200 ml of SDS Lysis Buffer. Chromatin was then sonicated to an average length of 0.5 Kb for three 30 sec. pulses at maximum power. Chromatin extracts were diluted 10 folds in Dilution Buffer and preincubated for 30 min at 4uC with 80 ml of Salmon Sperm DNA/ protein A Agarose. Twenty microlitres of diluted supernatant was kept for isolation of input DNA and to quantitate the DNA in different samples. After pelleting agarose by brief centrifugation, 2 mg of anti-Sp1 antiserum (test group) or 2 mg of b-actin antibody (irrelevant antibody control) was added to the supernatant fraction and incubated overnight at 4uC with rotation. In addition, perform a no antibody immunoprecipitation by incubating the supernatant fraction with Salmon Sperm DNA/ protein A Agarose for 1 h at 4uC. Add 60 ml of Salmon Sperm DNA/ protein A Agarose for 1 h at 4uC to collect the antibody/antigen-DNA complex. The chromatin bound to the protein A Agarose beads was eluted in 500 ml of freshly prepared elution buffer (1% SDS, 0.1 M NaHCO 3 ). After reversing crosslinks, the samples were deproteinized and phenol-chloroform extracted, then DNA was ethanol precipitated using yeast tRNA as a carrier. Pellets were resuspended in 50 ml of TE buffer for PCR analysis.
Each PCR reaction mixture contained 5 ml of immunoprecipitated chromatin in a final reaction volume of 20 ml. PCR mixtures were amplified for 35 cycles of 94uC for 30 s, 54uC for 30 s, and 72uC for 30 s. To amplify GC-box containing regions of p16
INK4a
promoter, the sequences of the primers used were as follows: ChIP1, 59-CCCCGATTCAATTTGGCAGTTAGG-39 (2505-2491); ChIP2, 59-CAGCGTTGGCAAGGAAGGAG GAC-39 (2342-2318). All primers were synthesized at AuGCT Biotechnology Co., Ltd (Beijing, China).
RNA interference(RNAi)
The target sequence against mRNA of Sp1 is 59-AUCACUCCA-UGGAUGAAAUGATT-39, which has been reported to be effective in some cell lines [30] . The hairpin siRNA(small interference RNA) template oligonucleotides containing the target sequence is designed following pSilencer neo instruction manual (Ambion, USA), and was chemically synthesized, annealed and inserted into the BamH I and Hind III site of pSilencer U6 2.1 neo vector (Ambion, USA).
Cells were transfected using Lipofectamin 2000 as specified by the manufacturer. The transfection mixture was left on the cells for 4 h, after which DMEM/20% serum without antibiotics was added. For efficient knockdown two more transfections were performed at 24 h and 48 h after the first transfection.
SA-b-Galactosidase activity at pH 6.0
Cells were washed twice in PBS, fixed in 3% formaldehyde, and washed again in PBS. The cells were incubated overnight at 37uC (without CO 2 ) with freshly prepared SA-b-Gal staining solution.
RESULTS
GC boxes are essential for p16
INK4a promoter activity in senescent human fibroblast cells
To determine the crucial GC-rich region of the human p16
INK4a
promoter, plasmid pGL3-620 that contained the p16 INK4a promoter with 620 bp upstream of the translation start site was used to generate GC boxes site mutation constructs pGL-Mut 1,5 (Tab. 1, and Fig. 1A ) respectively. These plasmids were then individually transfected into young (Fig. 1B) or senescent (Fig. 1C) human embryonic lung fibroblasts 2BS cells, and the promoter activities were measured by luciferase activities. Results showed that both in young and senescent cells, the mutation of GC-I, II or GC-IV reduced the promoter activity, while the mutation of GC-III or GC-V had less significant effect. What'more, the effect is stronger in the senescent cells than in the young ones. Therefore, GC-I, II and GC-IV, especially GC-II, are the key sites of action for Sp1 induced p16
INK4a expression. Furthermore, compared the relative value of these groups, it appears that the promoter activity of the human p16
INK4a is much more potent in senescent cells than in young ones.
Senescent cells contain potent Sp1/Sp3 binding activities to the GC boxes of the p16
INK4a promoter
To evaluate whether Sp proteins indeed binds to the GC boxes, gel electrophoretic mobility shift assays (EMSA) were performed. Oligo I including GC-I and GC-II and oligo II containing GC-IV were 59end labeled with [c-
32
P-]dATP and incubated with nuclear extracts from either young or senescent 2BS cells. The DNAprotein binding complexes were then analyzed on 5% polyacrylamide gel. As shown in Figure 2A , three specific DNA-protein binding complexes a, b and c, were detected by using oligo I, and all of the complexes disappeared with the addition of 100-fold molar excess of unlabeled competitor. To confirm the presence of Sp proteins in these complexes, Sp1 monoclonal antibodies or Sp3 polyclonal antibodies were incubated with the nuclear extracts before the DNA-protein binding complexes being analyzed on the gel. As shown in Figure 2A , complex a disappeared with the addition of Sp1-specific antibody; while complex b and c disappeared by using Sp3-specific antibody. Similar results were obtained with radio-labeled oligo II as probes, as demonstrated in Figure 2B . What is also worth noting is that Sp1/Sp3 DNA binding affinity in senescent cells is about 78% higher than that in young ones. This result is consistent with our earlier observation (Fig. 1) that the p16
INK4a promoter had much potent activity in senescent cells than that of young ones.
Sp1/Sp3 binds to p16
INK4a promoter in vivo
We next want to know whether Sp1 and/or Sp3 could bind to p16 INK4a promoter in living 2BS cells. For this purpose, we performed ChIP assay to monitor Sp1-and Sp3-occupancies in the p16
INK4a promoter using gene specific primers. Consistent with the results of EMSA, ChIP assays showed that Sp1/Sp3 indeed bound to p16
INK4a promoter in vivo and the binding activity in senescent cells was higher than in that of young cells by nearly 5 folds (Sp1) and 3.5 folds (Sp3) respectively (Fig. 3A, Fig. 3B ).
Sp1 induces p16
INK4a promoter activation and both To analyze the effect of Sp1 and Sp3 on p16 INK4a promoter, Sp1 and/or Sp3 expression vectors were co-transfected with pGL3-620 into young or senescent 2BS cells. As determined by luciferase activity, Sp1 activated the p16
INK4a promoter in a dose-dependent manner in both young and senescent 2BS cells, while Sp3 had little effect on it (Fig. 4) .
To confirm the effect of Sp1 on p16 INK4a promoter activity, mithramycin (MTR), which specifically blocks Sp1 and Sp3 binding to GC boxes, was added to 2BS cells after transfection with pGL3-620. As expected, the p16
INK4a promoter activity was inhibited by MTR in a dose-dependent manner in both young (Fig. 5A) and senescent (Fig. 5B) 2BS cells. Further, the p16 INK4a expression was also reduced at mRNA (Fig. 6A) and protein (Fig. 6B ) levels in 2BS cells, by 66% (mRNA level) and 48% (protein level) respectively, in the senescence group with 24 hours of MTR treatment.
As the mechanism of MTR treatment is blocking the transcription factors such as Sp family binding to GC-box, in this way, MTR could also affect the binding of other transcriptional factors to p16
INK4a promoter. To investigate the role of Sp1 specifically, Sp1 was knocked-down by RNAi to further confirm Sp1 binding to GC boxes is essential for the transcription of p16 INK4a (Fig. 7A) . Western Blot showed that si-Sp1 remarkably reduced the expression of Sp1, which in turn lead to a reduction of p16 INK4a expression (Fig. 7B) . The results from two aspects mentioned above suggest that not only Sp1 can activate p16
INK4a promoter in vivo but is required in maintenance of normal level of p16
INK4a protein in cultured human fibroblasts.
The binding affinity to p16
INK4a promoter is the key event but not the quantity of Sp1 enhanced during the aging process
The results mentioned above demonstrate that during the cell aging process, Sp1 contributes to the higher expression of p16 INK4a . However, which is responsible for this contribution: the quantity of the Sp1 expression or the binding affinity to p16
INK4a promoter? To elucidate this confusing problem, western analyses were performed using nuclear proteins from young and senescent 2BS cells. The results showed that the quantity of Sp1 and Sp3 proteins does not increase in the senescent cells. In another words, it contains the same amount of Sp1 and Sp3 proteins as that of young cells (Fig. 8) . Combined with the results observed in EMSA and ChIP assays, we thus conclude that the increased binding must be due to the increase of Sp1 DNA binding affinity, which in turn lead to the higher expression of p16
INK4a in senescent cells.
Sp1 increases SA-b-Gal activity whereas si-Sp1 expression inhibits SA-b-Gal activity SA-b-galactosidase staining is a common marker for cellular senescence. Usually, the b-galactosidase activity increases with the cell PD(population doubling) accumulating. The biological effect of over-expression (by Sp1 expression plasmid transfection) or knockdown (by RNAi approach) of Sp1 in 2BS cells were further evaluated by this method. The results showed that Sp1-overexpressed cells were strongly stained blue versus the control. However, there were only a few dispersed cells that were SA-bGal-stained in the Sp1 knocked-down cells (Fig. 9 ). All these outcomes manifested that RNAi-mediated silencing of Sp1 gene could delay senescence accompanied with decreased p16 INK4a promoter activity. The reporter construct pGL3-620 was co-transfected with pCMV-Sp1 or/and pCMVSp3 or control vector along with pRL-CMV in young (A) and senescent (B) 2BS cells. Luciferase assays were performed and normalized to the Renilla luciferase activity. The mean6S.E. from three independent experiments was used to express the relative luciferase activity. doi:10.1371/journal.pone.0000164.g004 
